Advertisement

Topics

STAT Plus: Pharmalittle: Novo may drop insulin prices; Teva employees push back against cuts

09:14 EDT 10 Aug 2017 | STAT

Novo Nordisk may drop insulin prices in the U.S. next year as Sanofi cuts prices of its own Lantus due to biosimilar competition.

Original Article: STAT Plus: Pharmalittle: Novo may drop insulin prices; Teva employees push back against cuts

NEXT ARTICLE

More From BioPortfolio on "STAT Plus: Pharmalittle: Novo may drop insulin prices; Teva employees push back against cuts"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Endocrine Disorders
Endocrine disorders are grouped into two categories: hormone imbalance - when a gland produces too much or too little of an endocrine hormone development of lesions (such as nodules or tumors) in the endocrine system, which may or may not affect...

Sanofi-Aventis
Sanofi-Aventis is a global pharmaceutical company with annual sales of $40,871m, placing it the second highest in the world. Although Sanofi-Aventis products are for a a very wide range of health problems, their major products are those for diabetes, o...